-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623A.O1.6 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas

Symposia: Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical trials, Combination therapy, Research, Adult, Lymphomas, Non-Hodgkin lymphoma, Elderly, Epidemiology, Clinical Research, B Cell lymphoma, Health outcomes research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Indolent lymphoma, Therapy sequence, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Registries, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 10:30 AM-12:00 PM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
Moderators:
Judith Trotman, FRACP, Concord Repatriation General Hospital and Akiva Diamond, MD, Baylor College of Medicine
Disclosures:
Trotman: Beigene: Research Funding; BMS: Research Funding; Cellectar: Research Funding; Janssen: Research Funding; Roche: Research Funding.
High impact abstracts related to the treatment of Mantle Cell Lymphoma and Hairy Cell leukemia
10:30 AM

Steven Le Gouill, MD, PhD1, Virginie de Wilde2*, Toby A. Eyre3,4*, Mary B. Callanan, PhD5*, Gandhi Damaj, MD, PhD6*, Alexis Claudel7*, Adrien Chauchet8*, Roch Houot, MD, PhD9*, Ronan Le Calloch10*, Victoria Cacheux11*, Marc André, MD, PhD12*, Franck Morschhauser13, Barbara Burroni, MD14*, David John Lewis, MD15*, Benoit Tessoulin16* and Aurore Touzart, MD, PhD17,18*

1Hematology Department, Institut Curie, Paris, France
2Hôpital Erasme, +université libre de Bruxelles, Bruxelles, Belgium
3Oxford University Hospitals NHS Trust, Oxford, United Kingdom
4Churchill Hospital, Oxford University, Oxford, United Kingdom
5CHU de Dijon, Université de Bourgogne, Dijon, France
6Hematology Institute, University Of Caen Normandie Hospital Center, Caen, France
7Hemato-biology, Henri Mondor University Hospital, CRETEIL, France
8Besançon University Hospital, Besançon, France
9Clinical Hematology, INSERM U1236, EFS, Hopital Pontchaillou, Rennes University Hospital, Rennes, France
10centre hospitalier de Cornouaille, quimper, France
11CHU Estaing, Clermont Ferrand, France
12CHU UCL Namur, Yvoir, Belgium
13Centre Hospitalier Universitaire de Lille - Hopital Claude Huriez, Lille, France
14Department of Pathology, Hôpital Cochin, Université de Paris, APHP, Paris, France
15University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
16Hematology Department, CHU Nantes, Nantes, France
17Laboratory of Onco-Hematology, Necker Enfants-Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
18INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France

10:45 AM

Jia Ruan, MD, PhD1, David A. Bond, MD, BS2, Bijal D Shah, MD3, John N. Allan, MD1, Sarah C. Rutherford, MD1, Caitlin Gribbin, MD1*, Zhengming Chen, PhD4*, Brittany Hobbie1*, Melinda Harbhajan1*, Tejasvi Sahni1*, Wayne Tam, MD5, Bhavneet Bhinder4*, Michael Sigouros4*, Giorgio Inghirami, MD6*, Selina Chen-Kiang, PhD7, Olivier Elemento, PhD, MS, BS8, Kami J. Maddocks, MD2, John P. Leonard, MD4 and Peter Martin, MD1

1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY
2Division of Hematology, The Ohio State University, Columbus, OH
3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
4Weill Cornell Medicine, New York, NY
5Northwell Health, New York
6Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
7Weill-Cornell Medical College, New York, NY
8Englander Institute for Precision Medicine/ Weill Cornell Medicine, Weill Cornell Medicine, New York, NY

11:00 AM

Mats Jerkeman, MD, PhD1, Karin Fahl Wader, MD, PhD2*, Ingrid Glimelius, MD, PhD3, Annika Pasanen, MD, PhD4*, Won Seog Kim5*, Louise Krüger Hansen6*, Jon Riise, MD, PhD7*, Martin Hutchings, MD, PhD8, Hashim Hussein Elhussein9*, Carsten Utoft Niemann, MD, PhD10*, Rasmus Rask Kragh Jørgensen, MSc11*, Tarec Christoffer El-Galaly, MD, DMSc, Prof12, Mats Ehinger, MD, PhD13*, Klaus Beiske, MD, PhD14*, Rose-Marie Amini15*, Michael Boe Møller16*, Marja-Liisa Karjalainen-Lindsberg, MD, PhD17* and Jacob Haaber Christensen, MD, PhD18*

1Division of Oncology, Skane University Hospital and Lund University, Lund, Sweden
2St Olav University Hospital, Department of Oncology, Trondheim, Norway
3Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Unit, Uppsala University, Uppsala, Sweden., Uppsala University, Uppsala, Sweden
4Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
5Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea, Republic of (South)
6Aarhus University, Aarhus, Denmark
7Department of Oncology, Oslo University Hospital, Oslo, NOR
8Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
9Rigshospitalet, Copenhagen, Denmark
10Department of Clinical Medicine, Dept. of Hematology, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark
11University of Aalborg, Aalborg, Denmark
12Department of Hematology, Aalborg Hospital, Aalborg, Denmark
13Lund University, Lund, SWE
14Oslo University Hospital, Oslo, Norway
15Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden
16Pathology, Odense University Hospital, Odense, Denmark
17Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
18Dept. of Hematology, Odense University Hospital, Odense, Denmark

11:15 AM

Tom van Meerten1*, M.J. Kersten, MD, PhD2*, Gloria Iacoboni, MD3*, Georg Hess, MD4*, Pim Mutsaers, MD5*, Alejandro Martín García-Sancho6*, Andre Goy, MD, MS7, Eva Gine, MD8, Brian T. Hill, MD, PhD9, Wen-Kai Weng, MD, PhD10, Martin Dreyling, MD11, Patrick M. Reagan, MD12, Krish Patel, MD13*, Ahmed Galal, MD, MSc, FRCPC14*, Charles Herbaux, MD, PhD15*, Robin Sanderson, FRCPath, PhD16, Dan Zheng, PhD17*, Justyna Kanska, PhD17*, Wangshu Zhang, PhD17*, Rita Damico Khalid, DO17*, Ioana Kloos, MD, FRCPC17* and Michael Wang, MD18

1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
2Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
3Vall d’Hebron University Hospital, Barcelona, Spain
4Johannes Gutenberg-Universität Mainz, Mainz, Germany
5Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
6Hematology Department, Salamanca University Hospital, IBSAL, CIBERONC, Salamanca, Spain
7John Theurer Cancer Center, Hackensack, NJ
8Hospital Clínic of Barcelona, IDIBAPS, CIBERONC, Barcelona, Spain
9Cleveland Clinic Foundation, Cleveland, OH
10Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
11Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany
12University of Rochester Medical Center, Rochester, NY
13Swedish Cancer Institute, Seattle, WA
14Carol G. Simon Cancer Center, Morristown, NJ
15Hématologie Clinique, CHU Montpellier, Montpellier, France
16King’s College Hospital, London, United Kingdom
17Kite, a Gilead Company, Santa Monica, CA
18The University of Texas MD Anderson Cancer Center, Houston, TX

11:30 AM

Yasmina I.M. Serroukh1*, Mathilde Fekom2*, Irma Khvedelidze2*, Ben Carpenter, MD3*, Herve Ghesquieres, MD, PhD4*, Ludovic Gabellier, MD, PhD5*, Jacques-Olivier Bay, MD, PhD6*, Didier Blaise, MD7*, Maurizio Musso8*, Patrice Chevallier, MD, PhD9, Edouard Forcade, MD, PhD10*, Anne Huynh, MD11*, Andy Peniket12*, Marek Trněný, MD, CSc13, Catherine Flynn14*, Shankara Paneesha15*, Andrew Clark16*, Charalampia Kyriakou, MD, PhD17, Anna Ossami Saidy18*, Bertram Glass, MD18*, Luca Castagna19*, Silvia Montoto, MD20 and Ali Bazarbachi, MD, PhD21

1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Leuven, Belgium
2European Bone Marrow Transplantation Lymphoma Working Party, Paris, France
3University College London Hospitals NHS Foundation Trust, London, United Kingdom
4Hospices Civils de Lyon, Lyon, France
5Hematology Departement, CHU Montpellier University Hospital, UMR-CNRS 5535, Montpellier, France
6CHU ESTAING, Clermont-Ferrand, France
7Programme de Transplantation & Therapie Cellulaire, Marseille, France
8Hematology Unit, Clinica La Maddalena Division of Onco-Hematology and Stem Cell Transplantation, Palermo, Italy
9CHU de Nantes, Nantes, France
10Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
11Hematology Department, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
12Oxford Radcliffe, Oxford, United Kingdom
13Charles University Hospital, Prague, Czech Republic
14Department of Haematology, St. James' Hospital, Dublin, Ireland
15Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Birmingham, United Kingdom
16Glasgow Royal Infirmary, Glasgow, United Kingdom
17Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
18Department of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany
19Bone Marrow Transplantation Unit AOR Villa Sofia Cervello, Palermo, Italy
20St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
21American University of Beirut Dept. of Medicine, Beirut, Lebanon

11:45 AM

Christopher Melani, MD1, Rahul Lakhotia, MBBS1, Stefania Pittaluga, MD, PhD2*, James D. Phelan, PhD1*, Jagan R. Muppidi, MD, PhD3*, Max J Gordon, MD1*, Yandan Yang, PhD1*, Weihong Xu1*, Theresa Davies-Hill2*, Da Wei Huang, MD1*, Craig J. Thomas, PhD4*, Michele Ceribelli, PhD4*, Frances A Tosto4*, Anna M Juanitez, RN1*, Amynah Pradhan, NP1*, Candis Morrison, NP, PhD1*, Atekelt Tadese, PA1*, Colleen Ramsower, BS, MB5*, Lisa M. Rimsza, MD5, Allison P. Jacob, MSc6, Heidi Simmons, PhD6, Seth M. Steinberg, PhD7*, Elaine S. Jaffe, MD8, Mark Roschewski, MD9, Louis M. Staudt, MD, PhD10 and Wyndham H Wilson, MD, PhD1*

1Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
2Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Lymphoid Malignancies Branch, National Institutes of Health, Bethesda, MD
4Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
5Department of Pathology and Laboratory Medicine, The University of Arizona, Tucson, AZ
6Adaptive Biotechnologies, Seattle, WA
7National Cancer Institute, National Institutes of Health, Bethesda, MD
8Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD
9National Cancer Institute, Bethesda, MD
10Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

*signifies non-member of ASH